Flagship Harbor Advisors LLC acquired a new stake in Charles River Laboratories International, Inc. (NYSE:CRL – Free Report) in the 4th quarter, HoldingsChannel reports. The fund acquired 1,282 shares of the medical research company’s stock, valued at approximately $237,000.
A number of other institutional investors have also recently made changes to their positions in the business. Wolff Wiese Magana LLC purchased a new position in Charles River Laboratories International in the 3rd quarter valued at approximately $32,000. Versant Capital Management Inc boosted its holdings in Charles River Laboratories International by 1,071.4% in the fourth quarter. Versant Capital Management Inc now owns 164 shares of the medical research company’s stock valued at $30,000 after purchasing an additional 150 shares during the period. Assetmark Inc. boosted its holdings in Charles River Laboratories International by 1,153.3% in the third quarter. Assetmark Inc. now owns 188 shares of the medical research company’s stock valued at $37,000 after purchasing an additional 173 shares during the period. Pinnacle Bancorp Inc. increased its holdings in Charles River Laboratories International by 52.0% during the 4th quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company’s stock worth $35,000 after purchasing an additional 65 shares during the period. Finally, Wilmington Savings Fund Society FSB acquired a new stake in Charles River Laboratories International in the 3rd quarter valued at about $59,000. Institutional investors and hedge funds own 98.91% of the company’s stock.
Insider Buying and Selling at Charles River Laboratories International
In other news, Director Richard F. Wallman sold 6,621 shares of the business’s stock in a transaction that occurred on Thursday, November 7th. The stock was sold at an average price of $216.12, for a total value of $1,430,930.52. Following the transaction, the director now owns 12,386 shares of the company’s stock, valued at approximately $2,676,862.32. The trade was a 34.83 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 1.30% of the stock is owned by company insiders.
Charles River Laboratories International Stock Performance
Charles River Laboratories International (NYSE:CRL – Get Free Report) last issued its quarterly earnings data on Wednesday, November 6th. The medical research company reported $2.59 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.43 by $0.16. Charles River Laboratories International had a net margin of 10.44% and a return on equity of 14.29%. The company had revenue of $1.01 billion for the quarter, compared to the consensus estimate of $975.99 million. During the same period last year, the firm posted $2.72 EPS. Charles River Laboratories International’s revenue for the quarter was down 1.6% on a year-over-year basis. As a group, equities analysts predict that Charles River Laboratories International, Inc. will post 10.18 EPS for the current year.
Wall Street Analyst Weigh In
A number of research firms recently weighed in on CRL. William Blair lowered shares of Charles River Laboratories International from an “outperform” rating to a “market perform” rating in a research note on Wednesday, January 22nd. UBS Group restated a “neutral” rating and issued a $185.00 price objective (down from $250.00) on shares of Charles River Laboratories International in a report on Friday, January 17th. Bank of America lowered their target price on shares of Charles River Laboratories International from $220.00 to $210.00 and set a “neutral” rating for the company in a research note on Friday, December 13th. The Goldman Sachs Group cut their price target on Charles River Laboratories International from $220.00 to $190.00 and set a “buy” rating on the stock in a research note on Thursday, January 23rd. Finally, TD Cowen upped their price objective on Charles River Laboratories International from $203.00 to $227.00 and gave the stock a “hold” rating in a research report on Monday, November 11th. Three analysts have rated the stock with a sell rating, thirteen have given a hold rating and one has issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $204.38.
Check Out Our Latest Stock Analysis on CRL
Charles River Laboratories International Company Profile
Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).
Featured Articles
- Five stocks we like better than Charles River Laboratories International
- How to Invest in the Best Canadian Stocks
- How to Short Sell Stocks Like a Pro: Strategies and Tips
- What is Forex and How Does it Work?
- 3 Steel Stocks Soaring After Tariff Announcements
- What is the NASDAQ Stock Exchange?
- Top Analysts’ Picks for 2025: 3 of Morgan Stanley’s Favorites
Want to see what other hedge funds are holding CRL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Charles River Laboratories International, Inc. (NYSE:CRL – Free Report).
Receive News & Ratings for Charles River Laboratories International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International and related companies with MarketBeat.com's FREE daily email newsletter.